Summary of Significant Accounting Policies - Schedule of Company Revenue and Adjusted EBITDA by Segment (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Segment Revenue
Total Revenue		$ 271,893	$ 243,920	$ 305,463
Segment Adjusted EBITDA
Total Adjusted EBITDA		(150,740)	(76,525)	(147,188)
Net income (loss)		(217,490)	(183,619)	(250,863)
Adjustments
Interest (income) expense, net		(277)	(255)	(6,244)
Other (income) expense, net		83	(1,322)	(1,340)
Change in fair value of warrant liabilities		(32,989)	0	0
Income tax benefit		(3,480)	0	0
Depreciation and Amortization		18,899	20,246	22,610
Amortization Of Acquired Intangible Assets		7,269
Stock-based compensation expense		57,933	88,425	44,838
Stock-based compensation expense				43,957
Restructuring and other charges (1)	[1]	0	0	44,692
Acquisition-related costs(2)	[2]	9,362	0	0
Litigation settlement (3)	[3]	9,950	0	0
Total Adjusted EBITDA		(150,740)	(76,525)	(147,188)
Consumer And Research Services [Member]
Segment Revenue
Total Revenue		271,893	243,866	299,907
Segment Adjusted EBITDA
Total Adjusted EBITDA		(30,112)	12,796	(65,845)
Therapeutics
Segment Revenue
Total Revenue			54	5,556
Segment Adjusted EBITDA
Total Adjusted EBITDA		(76,944)	(58,734)	(52,883)
Unallocated Corporate [Member]
Segment Adjusted EBITDA
Total Adjusted EBITDA		$ (43,684)	$ (30,587)	$ (28,460)

[1] For the year ended March 31, 2020, restructuring includes $0.9 million of stock-based compensation expense related to restructuring activities.

[2] For the fiscal year ended March 31, 2022, acquisition-related costs primarily consisted of advisory, legal and consulting fees related to the Lemonaid Acquisition

[3] For the fiscal year ended March 31, 2022, litigation settlement is litigation cost net of insurance recoveries, which is not expected to occur on a recurring basis and not part of the Company's normal and continued business activity.